NEW YORK (GenomeWeb News) – SeraCare Life Sciences shareholders have approved the $82 million sale of the firm to private equity firm Linden Capital Partners, SeraCare announced today.
Under the terms of the deal, originally announced in February, holders of outstanding shares of SeraCare's common stock will receive $4 per share. The deal is expected to close on Friday.
The Milford, Mass.-based company will be merged with Project Plasma Holding and Project Plasma Merger, affiliates of Linden.
SeraCare makes life sciences tools including molecular biomarkers and controls.
In late-afternoon trading on the Nasdaq shares of SeraCare were up a fraction of 1 percent at $4.